Drug Profile

BI 54903/olodaterol fixed-dose combination

Alternative Names: BI-54903/olodaterol

Latest Information Update: 10 Oct 2014

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Class Amines; Antiasthmatics; Benzoxazines; Bronchodilators; Corticosteroids; Ketones
Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

10 Oct 2014 No development reported - Phase-I for Asthma (In volunteers) in Germany (Inhalation)
21 Nov 2011 Boehringer Ingelheim withdraws a phase II trial in Asthma prior to enrolment in France and Germany (NCT01428622)
01 Mar 2009 Phase-I clinical trials in Asthma (In volunteers) in Germany (Inhalation)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com